Limited utility of rapamycin in severe, refractory Wegener's granulomatosis
- PMID: 19012360
- DOI: 10.3899/jrheum.080664
Limited utility of rapamycin in severe, refractory Wegener's granulomatosis
Abstract
Objective: We report our experience using rapamycin in patients with Wegener's granulomatosis (WG) who failed to achieve remission with conventional treatment.
Methods: Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively.
Results: Four patients treated with rapamycin sustained remissions of at least 6 months' duration while receiving prednisone<or=10 mg/day; 2 relapsed during followup. Five patients discontinued rapamycin due to continued disease activity, cancer, or adverse events.
Conclusion: Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen.
Similar articles
-
Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations.J Rheumatol. 2008 Oct;35(10):2017-23. Epub 2008 Aug 1. J Rheumatol. 2008. PMID: 18688911 Clinical Trial.
-
Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.Arthritis Rheum. 2003 Aug;48(8):2299-309. doi: 10.1002/art.11075. Arthritis Rheum. 2003. PMID: 12905485 Clinical Trial.
-
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).Arthritis Rheum. 2005 Jul;52(7):2168-78. doi: 10.1002/art.21117. Arthritis Rheum. 2005. PMID: 15986348 Clinical Trial.
-
Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.Lupus. 2008 Sep;17(9):832-6. doi: 10.1177/0961203308089693. Lupus. 2008. PMID: 18755865 Review.
-
Wegener's granulomatosis: managing more than inflammation.Curr Opin Rheumatol. 2008 Jan;20(1):10-6. doi: 10.1097/BOR.0b013e3282f18bef. Curr Opin Rheumatol. 2008. PMID: 18281851 Review.
Cited by
-
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Nat Rev Nephrol. 2016 Oct;12(10):587-609. doi: 10.1038/nrneph.2016.108. Epub 2016 Aug 1. Nat Rev Nephrol. 2016. PMID: 27477490 Free PMC article. Review.
-
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Nat Rev Rheumatol. 2016 Mar;12(3):169-82. doi: 10.1038/nrrheum.2015.172. Epub 2015 Dec 24. Nat Rev Rheumatol. 2016. PMID: 26698023 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical